Biomarin Pharmaceutical Inc BMRN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EST
79.17UNCH (UNCH)
Volume
20,605
Close
79.17quote price arrow up+1.74 (+2.25%)
Volume
2,260,746
52 week range
68.25 - 131.94

...

Loading . . .

KEY STATS

  • Open78.81
  • Day High80.50
  • Day Low78.08
  • Prev Close77.43
  • 52 Week High131.94
  • 52 Week High Date07/21/20
  • 52 Week Low68.25
  • 52 Week Low Date03/23/20
  • Market Cap14.372B
  • Shares Out181.53M
  • 10 Day Average Volume1.33M
  • Dividend-
  • Dividend Yield-
  • Beta0.58
  • 1 Year % Change-12.29

RATIOS/PROFITABILITY

  • EPS (TTM)4.37
  • P/E (TTM)18.14
  • Fwd P/E (NTM)-201.96
  • EBITDA (MRQ)27.455M
  • ROE (MRQ)23.91%
  • Revenue (MRQ)1.863B
  • Gross Margin (MRQ)73.48%
  • Net Margin (MRQ)45.74%
  • Debt To Equity (MRQ)35.92%

EVENTS

  • Earnings Date04/27/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Biomarin Pharmaceutical Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS)...
Jean-Jacques Bienaime
Chairman
Brian Mueller CPA
Chief Financial Officer
Andrea Acosta
Chief Accounting Officer
Jeff Ajer
Executive Vice President
C. Greg Guyer Ph.D.
Executive Vice President
Address
105 Digital Dr
Novato, CA
94949-8703
United States